GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » Retained Earnings

Botanix Pharmaceuticals (ASX:BOT) Retained Earnings : A$-82.39 Mil (As of Dec. 2023)


View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Botanix Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2023 was A$-82.39 Mil.

Botanix Pharmaceuticals's quarterly retained earnings declined from Dec. 2022 (A$-72.37 Mil) to Jun. 2023 (A$-76.92 Mil) and declined from Jun. 2023 (A$-76.92 Mil) to Dec. 2023 (A$-82.39 Mil).

Botanix Pharmaceuticals's annual retained earnings declined from Jun. 2021 (A$-54.60 Mil) to Jun. 2022 (A$-67.77 Mil) and declined from Jun. 2022 (A$-67.77 Mil) to Jun. 2023 (A$-76.92 Mil).


Botanix Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Botanix Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals Retained Earnings Chart

Botanix Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.53 -51.26 -54.60 -67.77 -76.92

Botanix Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.11 -67.77 -72.37 -76.92 -82.39

Botanix Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Botanix Pharmaceuticals  (ASX:BOT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Botanix Pharmaceuticals (ASX:BOT) Business Description

Traded in Other Exchanges
Address
661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007
Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines